IQVIA (NYSE:IQV) Updates FY 2025 Earnings Guidance

IQVIA (NYSE:IQV) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 11.700-12.100 for the period, compared to the consensus estimate of 11.880. The company issued revenue guidance of $15.7 billion-$16.1 billion, compared to the consensus revenue estimate of $16.0 billion.

IQVIA Trading Up 2.5 %

Shares of NYSE:IQV opened at $205.12 on Thursday. IQVIA has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $37.23 billion, a PE ratio of 26.92, a P/E/G ratio of 2.15 and a beta of 1.48. The company’s 50-day moving average price is $200.29 and its 200 day moving average price is $219.97.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. Sell-side analysts anticipate that IQVIA will post 10.18 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Morgan Stanley decreased their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Barclays cut their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $254.53.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.